Project Grant R01CA297338
Award Date
3/17/25
Completion Date
1/31/30
Dollars Obligated
$703K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $392,410 Project Grant award, issued by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports research focused on uncovering the drivers of tumor heterogeneity and the transition to neuroendocrine prostate cancer (NEPC). The award recipient, Weill Medical College of Cornell University, will utilize a genetically-engineered mouse model and organoid-based platforms to investigate a previously undescribed tumor subpopulation that may represent a...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $169,500 to Weill Medical College of Cornell University to conduct research aimed at identifying key metabolic mechanisms that regulate the differentiation of CD8+ T cells and their anti-tumor efficacy.
The goals of the project are to: 1) Use a CRISPR/Cas9 screen to identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on identifying novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to stimulate anti-tumor CD8+ T cell responses for the treatment of triple-negative breast cancer (TNBC). The $460,977 award to Health Research, Inc. at Roswell Park Comprehensive Cancer Center will fund research to 1) identify candidate CNE peptide sequences generated by chemotherapy-induced...
This federal Project Grant award, valued at $237,724, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Weill Medical College of Cornell University. The grant will fund research to determine if the p53 mutational status of a tumor is a key determinant of the ability of radiation therapy to induce cancer cell-intrinsic interferon-I pathway activation and in situ immunization. The research will utilize several p53-isogenic mouse and human cancer cell...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $122,032 to Weill Medical College of Cornell University to conduct research exploring the role of aberrant splicing in cancer cell heterogeneity and its potential as a target for immunotherapeutic strategies.
The key products or services to be delivered include:
Utilizing the GOT-SPLICE technology to study mutations in splicing factors (SRSF2, U2AF1, ZRSR2) in myelodysplastic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute to conduct research assessing germline variants associated with immune-related adverse events (IRAEs) following immune checkpoint inhibitor (ICI) cancer treatments. The overarching goals are to:
Conduct the largest genome-wide association study (GWAS) for IRAEs, aggregating data across over 13,000 ICI patients to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $107,948 to the Icahn School of Medicine at Mount Sinai to investigate the role of the interferon gamma (IFNγ) signaling pathway in lung cancer tumor microenvironment and response to immune checkpoint blockade therapy. The key objectives are to:
Investigate the impact of knocking out the SOCS1 gene, a negative regulator of the IFNγ pathway, on tumor immune composition and response...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) totaling $620,820 supports research to investigate mechanisms of immune therapy resistance. The key objectives are to:
Understand the molecular regulation and transcriptional mechanisms of the CREB5 transcription factor, which was identified as a driver of immune evasion in preliminary studies.
Characterize the CREB5-interacting proteins that mediate increased deposition of collagen...
This $160,642 Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), supports research aimed at characterizing the role of oncogenic NRAS mutations in leukemogenesis and therapeutic resistance in Acute Myeloid Leukemia (AML) with IDH1 mutations. The grant recipient, Weill Medical College of Cornell University, will utilize genetically engineered mouse models and patient-derived xenograft models to define how NRAS mutations...
This $194,778 federal Project Grant awarded by the National Cancer Institute (NCI) under CFDA 93.395 Cancer Treatment Research supports the Weill Medical College of Cornell University in optimizing strategies to improve NCI-sponsored clinical trial participation across the Weill Cornell Medicine - Meyer Cancer Center sphere in New York City.
The project aims to expand access and increase enrollment in NCI-sponsored cancer clinical trials for the diverse and underserved patient population...